Assessment of a New Closed-loop Algorithm in Type 1 Diabetes (Saddle Point Model Predictive Control : SP-MPC) (PPA) (PPA)
Prospective, Monocentric, Crossover Randomized Trial, to Assess a New Closed-loop Algorithm in Type 1 Diabetes (Saddle Point Model Predictive Control : SP-MPC)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Ten patients will be assessed during a closed-loop night and an open-loop night in random order.
The primary objective is to assess the ability of SP-MPC controler to maintain euglycemia and avoid hypoglycaemia during the night, compared to open loop in type 1 diabetic patients treated by insulin pump.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Rennes, France, 35033
- Rennes University Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients with type 1 diabetes (C peptide negative) :
- 18 to 70 year old,
- with type 1 diabetes for more than 3 years,
- treated by insulin pump for more than 3 months,
- with previous CGM holter allowing preliminary settting of some of the SP-MPC parameters
- able to provide written informed consent.
Exclusion Criteria:
- pregnancy or breastfeeding,
- severe non stabilized diabetic retinopathy,
- cardiovascular event in the previous 6 months,
- infectious diseases with recent fever,
- anemia (hemoglobin < 11g/l),
- HbA1c > 10%,
- Current or recent (less than 4 weeks) oral or injectable corticosteroid treatment,
- creatinine clearance <40ml/mn,
- chronic alcoholism (weekly consumption of alcohol > 280g for men and > 140g for women),
- adults legally protected (under judicial protection, guardianship, or supervision), persons deprived of their liberty
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: open-loop night
|
During the open-loop night the patient is using his insulin pump as usual
|
|
Experimental: closed-loop night
|
During the closed-loop night glucose values measured by the sensor are collected every 15 minutes.
The data are entered into the SP-MPC controler that calculate the insulin dose to be delivered.
A diabetologist validates the insulin dose before the infusion (manually bolus infusion)
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Assessment of time spent in target range (glycemia between 70 and 145 mg/dl) and in hypoglycemia (glycemia <70 mg/dl), during the night (11 PM to 8 AM)
Time Frame: 6 weeks
|
Assessment of the ability of SP-MPC controler to maintain euglycemia and avoid hypoglycaemia during the night, compared to open loop in type 1 diabetic patients treated by insulin pump
|
6 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Assessment of time spent above 70 mg/dl, between 70-145 or 145-180 mg/dl and above 180 mg/dl (interstitial glucose) in the late post prandial period (9 to 11 PM) and during the night (11 PM to 8 AM)
Time Frame: 6 weeks
|
Assessment of hypoglycemia and hyperglycemia cases, average glycemic balance, glycemic variability, insulin doses
|
6 weeks
|
|
Assessment of hypoglycemia occurrence during the night
Time Frame: 6 weeks
|
6 weeks
|
|
|
Assessment of area under the curves (70-180mg/dl) during the night
Time Frame: 6 weeks
|
6 weeks
|
|
|
Assessment of Low Blood Glucose Index (LBGI), High Blood Glucose Index (HBGI) and CONGA Index
Time Frame: 6 weeks
|
6 weeks
|
|
|
Assessment of insulin doses delivered between 9 PM and 8 AM
Time Frame: 6 weeks
|
6 weeks
|
|
|
Assessment of number of controller propositions rejected for security reasons
Time Frame: 6 weeks
|
6 weeks
|
|
|
Assessment of glucose values during the night (glycemia and interstitial glucose values)
Time Frame: 6 weeks
|
6 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Isabelle Guilhem, Rennes University Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2013-A01604-41
- 35RC13_8806_PPA (Other Identifier: Rennes University Hospital)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.